Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of romiplostim in thrombocytopenic subjects with myelodysplastic syndromes
2007-001516-24Phase 2Completed
- Sponsor
- Amgen
- Start
- Jun 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in myelodysplastic syndrome (MDS), sponsored by Amgen. Started Jun 2007; status: completed.
02
Drugs
romiplostim
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2007-001516-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001516-24.